Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Amends Revolving Credit Facility, Enters Agreement for Term Loan Credit Facility

NEW YORK (GenomeWeb) – Laboratory Corporation of America has amended and restated an existing senior revolving credit facility in the principal amount of $1 billion and entered into a five-year term loan credit facility in the principal amount of $1 billion, it said in a recent filing with the US Securities and Exchange Commission.

The new five-year revolving credit facility provides LabCorp with the ability to increase the facility by up to $250 million on top of the $1 billion principal amount. It also provides for a subfacility of up to $100 million for swing line borrowings and a subfacility of up to $125 million for issuances of letters of credit.

Bank of America is the swing line lender and a letter of credit issuer, as well as the administrative agent for a group of financial institutions that are providing the revolving credit facility.

The new revolving credit facility can be used for general corporate purposes, including working capital, capital expenditures, the funding of share repurchases and other certain payments, acquisitions, and other investments.

The new facility amends and restates an existing credit facility agreed to in December 2011. As of Dec. 19, there were no outstanding borrowings under the new revolving credit facility, and existing letters of credit totaling $42 million were continued under the facility, LabCorp said.

Also, LabCorp has entered into a new term loan credit facility with Bank of America acting as the administrative agent. The facility can be used to pay all or part of LabCorp's $6.1 billion acquisition of Covance. If the deal is not completed by June 2, 2015, the commitments under the term loan credit facility will automatically terminate, LabCorp said in its SEC document. 

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.